Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
AUPH has been the subject of a number of other research reports. FBR & Co reiterated an “outperform” rating and set a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Tuesday, March 14th. HC Wainwright reduced their price objective on Aurinia Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, December 30th. Leerink Swann upped their price objective on Aurinia Pharmaceuticals from $7.00 to $11.00 and gave the company an “outperform” rating in a research report on Thursday, March 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, March 3rd. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $8.92.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 14.03% during mid-day trading on Monday, hitting $8.78. The stock had a trading volume of 27,745,739 shares. The company’s market cap is $469.10 million. Aurinia Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $10.54. The stock’s 50-day moving average is $4.73 and its 200 day moving average is $3.34.
var userip;Your IP Address: document.write(userip);
A number of hedge funds have recently bought and sold shares of AUPH. Redmile Group LLC boosted its stake in Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock worth $565,000 after buying an additional 159,200 shares during the period. Oxford Asset Management purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $211,000. Acuta Capital Partners LLC purchased a new stake in Aurinia Pharmaceuticals during the fourth quarter worth approximately $2,100,000. SG Americas Securities LLC purchased a new stake in Aurinia Pharmaceuticals during the third quarter worth approximately $1,123,000. Finally, Creative Planning purchased a new stake in Aurinia Pharmaceuticals during the third quarter worth approximately $181,000. Institutional investors own 7.96% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.